BMS-751324

• Description :

  BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA) . BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model[1].

• CAS Number :

  [948842-66-8]

• UNSPSC :

  12352005

• Target :

  P38 MAPK; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bms-751324.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC1=CC=C(C(NC2CC2)=O)C=C1NC3=NC=NN4C3=C(C)C(C(N(C(OCOC(CC5=CC=C(OP(O)(O)=O)C=C5)=O)=O)CCC)=O)=C4

• Molecular Formula :

  C32H35N6O10P

• Molecular Weight :

  694.63

• References & Citations :

  [1]Liu C, et al. Discovery of 4- (5- (cyclopropylcarbamoyl) -2-methylphenylamino) -5-methyl-N-propylpyrrolo [1, 2-f][1, 2, 4] triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases[J]. Journal of medicinal chemistry, 2010, 53 (18) : 6629-6639.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported